# US 9,796,704 B2 · Substituted quinazolines as receptor-type kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,796,704 B2
- Document ID: US9796704B2
- Status: Granted
- Kind: B2
- Application number: 14/845,763
- Filed: 2015-09-04
- Published: 2016-05-12
- Granted: 2017-10-24
- Earliest claimed: 2002-07-15
- Assignees: Symphony Evolution, Inc.
- Applicants: Symphony Evolution, Inc.
- Inventors: Kenneth D. Rice; Neel K. Anand; Joerg Bussenius; Simona Costanzo; Abigail R. Kennedy; Csaba J. Peto; Tsze H. Tsang; Charles M. Blazey
- Web page: https://patentgrep.com/patent/US9796704B2

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/94: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 451/06: Oxygen atoms
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of structural formula I, for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

## Claims

### Claim 1

A method of inhibiting a receptor tyrosine kinase in a cell, wherein the receptor tyrosine kinase is selected from the group consisting of kinase insert domain receptor, epidermal growth factor receptor and ErbB2, comprising contacting the cell with a compound of Formula I:
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
R1 is methyl;
R2 is —H or halogen;
R3 is —H or R4;
R4 is lower alkyl, lower arylalkyl or aryl, wherein lower alkyl and aryl are independently and optionally substituted with one, two or three halogen; or
R3 and R4, taken together with the nitrogen to which they are attached, form morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl, each optionally substituted with one, two or three alkyl;
q is 0, 1, 2, 3, 4, or 5;
Z is —NR5—;
R5 is —H;
M1-M2-M3-M4-is formula II:
wherein X1, X2, and optionally X3, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X1, X2, and X3; wherein,
each X1 is independently —C(R6)R7—, —O—, —S(O)0-2- or —NR8—;
each X2 is independently —C(R6)— or a bridgehead nitrogen;
each X3 is independently —C(R6)R7—, —O—, —S(O)0-2- or —NR8—;
provided that for X1, X2 and X3, there are neither nitrogen-nitrogen annular bonds, nor germinal dinitrogen substitutions;
E is absent;
Y is —CH2—;
provided that Y is not directly attached to any oxygen, sulfur or nitrogen heteroatom of X1, X2 or X3;
m and p are each independently 1, 2, 3, or 4;
n is 0;
R6 and R7 are each independently —H, halogen, trihalomethyl, —CN, —NH2, —NO2, —OR3, —N(R3)R4, —S(O)0-2R4, —SO2N(R3)R4, —CO2R3, —C(O)N(R3)R4, —N(R3)SO2R4, —N(R3)C(O)R3, —NCO2R3, —C(O)R3, lower alkyl, aryl or lower arylalkyl; or
R6 and R7, taken together, form oxo; or
R6 and R7, taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl, optionally containing at least one additional heteroatom selected from the group consisting of nitrogen, oxygen, sulfur and phosphorus, wherein the spirocyclyl is optionally substituted with one or two alkyl;
provided that when Y is attached to an X1 or X3 that is —C(R6)R7—, one of R6 and R7 is absent; and
R8 is R3, —SO2N(R3)R4, —CO2R3, —C(O)N(R3)R4, —SO2R4 or —C(O)R3;
provided that the X1 atoms of one bridge of the saturated bridged ring system, when combined with both X2 bridgehead atoms of the saturated bridged ring system, represent:
either a pyrrolidine ring or a piperidine ring, and any atom, X1 or X2, of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of —OC(O)CH2—, —CH2OC(O)—, —OC(O)CH2CH2—, —CH2OC(O)CH2—, —CH2CH2OC(O)—, —OC(O)CH2NH—, —OC(O)CH2N(C1-4alkyl)-, and —OC(O)CH2O—; and
either a piperazine ring or a 4-(C1-4 alkyl)-piperazine ring, and any atom, X1 or X2, of either of said piperazine ring or said 4-(C1-4 alkyl)-piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4-(C1-4 alkyl)-piperazine ring, cannot be one of —CH2OC(O)CH2—, —CH2CH2OC(O)—, and either of the two aforementioned bridges substituted by one or two C1-2alkyl groups; and
a piperazine ring, and any atom, X1 or X2, of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot be —C(O)OCH2CH2—, —CH2OC(O)CH2—, —C(O)OCH2CH2— substituted with one or two C1-2 alkyl groups, or —CH2OC(O)CH2— substituted with one or two C1-2 alkyl groups (but only when the four above mentioned bridges are attached to the 3-position of said piperazine ring via their left-hand end as depicted above); and
a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of —(CH2)g—, —CH2WCH2—, —CH2WCH2CH2—, and —CH2CH2WCH2—, wherein W is —O—, —S(O)0-2—, —NH—, or —N(C1-4 alkyl)-, wherein g is 2, 3 or 4.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
R2 is halogen;
q is 1, 2 or 3; and
M1-M2-M3-M4-is formula V or formula VI:
R8 is —H, lower alkyl, —CO2R3, —C(O)N(R3)R4, —SO2R4 or —C(O)R3;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-(1-methylethyl)octahydro cyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 aR, 5r, 6aS)-2-(1-methylethyl)octa hydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3 aR, 5r,6aS)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3 aR,5r,6aS)-octahydro cyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3 aR, 5r, 6aS)-5-[({4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl oxy)quinazolin-7-yl}oxy)methyl]hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 aR, 5r, 6aS)-2-(methyl sulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3 aR,5r,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 aR, 5r,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 aR, 5r, 6aS)-2-methyloctahydrocyclo penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3 aR,5r,6aS)-2-methyloctahydrocyclopenta-[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4, 5-dichloro-2-fluorophenyl)-7-({[(3 aR,5r,6aS)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3 aR, 5r, 6aS)-2-methyl octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3 aR, 5r,6aS)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3 aR, 5r, 6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3 aR, 5r, 6aS)-2-ethyloctahydrocyclo penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3 aR,5r,6 aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
1,1-dimethylethyl (3 aR,6aS)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]methyl]oxy}quinazolin-4-amine; and
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the receptor tyrosine kinase is kinase insert domain receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the receptor tyrosine kinase is epidermal growth factor receptor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the receptor tyrosine kinase is ErbB2.
